The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy

Eric J. Mao, Uma Mahadevan

Research output: Contribution to journalEditorial

1 Citation (Scopus)

Abstract

Data in support of the safety of biologic use during pregnancy continues to grow. Utilizing a national French database with linkage between mothers and children, Luu et al. demonstrated that anti-tumor necrosis factor (anti-TNF) therapy exposure did not increase infection risk in children, though the mothers had higher rates of infection. Stopping therapy prior to 24 weeks gestation led to a higher rate of disease flares in the mother with no benefit to the infant compared to continued therapy.

Original languageEnglish (US)
Pages (from-to)1590-1591
Number of pages2
JournalAmerican Journal of Gastroenterology
Volume113
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Tumor Necrosis Factor-alpha
Mothers
Pregnancy
Implosive Therapy
Infection
Therapeutics
Databases
Safety

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

The Debate is Over : Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy. / Mao, Eric J.; Mahadevan, Uma.

In: American Journal of Gastroenterology, Vol. 113, No. 11, 01.11.2018, p. 1590-1591.

Research output: Contribution to journalEditorial

@article{a981e32b8d184020aa53adfcfca0527b,
title = "The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy",
abstract = "Data in support of the safety of biologic use during pregnancy continues to grow. Utilizing a national French database with linkage between mothers and children, Luu et al. demonstrated that anti-tumor necrosis factor (anti-TNF) therapy exposure did not increase infection risk in children, though the mothers had higher rates of infection. Stopping therapy prior to 24 weeks gestation led to a higher rate of disease flares in the mother with no benefit to the infant compared to continued therapy.",
author = "Mao, {Eric J.} and Uma Mahadevan",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41395-018-0254-x",
language = "English (US)",
volume = "113",
pages = "1590--1591",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - The Debate is Over

T2 - Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy

AU - Mao, Eric J.

AU - Mahadevan, Uma

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Data in support of the safety of biologic use during pregnancy continues to grow. Utilizing a national French database with linkage between mothers and children, Luu et al. demonstrated that anti-tumor necrosis factor (anti-TNF) therapy exposure did not increase infection risk in children, though the mothers had higher rates of infection. Stopping therapy prior to 24 weeks gestation led to a higher rate of disease flares in the mother with no benefit to the infant compared to continued therapy.

AB - Data in support of the safety of biologic use during pregnancy continues to grow. Utilizing a national French database with linkage between mothers and children, Luu et al. demonstrated that anti-tumor necrosis factor (anti-TNF) therapy exposure did not increase infection risk in children, though the mothers had higher rates of infection. Stopping therapy prior to 24 weeks gestation led to a higher rate of disease flares in the mother with no benefit to the infant compared to continued therapy.

UR - http://www.scopus.com/inward/record.url?scp=85055293564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055293564&partnerID=8YFLogxK

U2 - 10.1038/s41395-018-0254-x

DO - 10.1038/s41395-018-0254-x

M3 - Editorial

C2 - 30337704

AN - SCOPUS:85055293564

VL - 113

SP - 1590

EP - 1591

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 11

ER -